MedTrace Logo

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

NCT06772220 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-01-13

No results posted yet for this study

Summary

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Conditions

  • Parkinson&Amp;#39;s Disease

Interventions

DIETARY_SUPPLEMENT

Folic Acid 1 MG

Folic Acid 1mg per day

DIETARY_SUPPLEMENT

Vitamin B6 25 MG

Vitamin B6, 25mg per day

DIETARY_SUPPLEMENT

Vitamin B12

Vitamin B12, 1,000 ug per day

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Joseph Quinn, MD · Oregon Health & Science University (OHSU)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772220 on ClinicalTrials.gov